Building CRISPR Gene Therapies for the Central Nervous System
JAMA Neurology · 01.03.2024 · 81 (3) · 283
DOI: 10.1001/jamaneurol.2023.4983 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JAMA Neurology, erschienen am 01.03.2024. Verfasst von Sally E Salomonsson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Clustered Regularly Interspaced Short Palindromic Repeats. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Importance Gene editing using clustered regularly interspaced short palindromic repeats (CRISPR) holds the promise to arrest or cure monogenic disease if it can be determined which genetic change to create without inducing unintended cellular dysfunction and how to deliver this technology to the target organ reliably and safely. Clinical trials for blood and liver disorders, for which delivery of CRISPR is not limiting, show promise, yet no trials have begun for central nervous system (CNS) indications. Observations The CNS is arguably the most challenging target given its innate exclusion of large molecules and its defenses against bacterial invasion (from which CRISPR originates). Herein, the types of CRISPR editing (DNA cutting, base editing, and templated repair) and how these are applied to different genetic variants are summarized. The challenges of delivering genome editors to the CNS, including the viral and nonviral delivery vehicles that may ultimately circumvent these challenges, are discussed. Also, ways to minimize the potential in vivo genotoxic effects of genome editors through delivery vehicle design and preclinical off-target testing are considered. The ethical considerations of germline editing, a potential off-target outcome of any gene editing therapy, are explored. The unique regulatory challenges of a human-specific therapy that cannot be derisked solely in animal models are also discussed. Conclusions and Relevance An understanding of both the potential benefits and challenges of CRISPR gene therapy better informs the scientific, clinical, regulatory, and timeline considerations of developing CRISPR gene therapy for neurologic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco.
- Department of Neurology, Memory and Aging Center, University of California, San Francisco.
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
Zitieren
APA
Salomonsson, S. E., & Clelland, C. D. (2024). Building CRISPR Gene Therapies for the Central Nervous System. JAMA Neurology, 81(3), 283. https://doi.org/10.1001/jamaneurol.2023.4983
Vancouver
Salomonsson SE, Clelland CD. Building CRISPR Gene Therapies for the Central Nervous System. JAMA Neurology. 2024;81(3):283. doi:10.1001/jamaneurol.2023.4983
BibTeX
@article{Salomonsson2024,
author = {Salomonsson, Sally E and Clelland, Claire D},
title = {Building CRISPR Gene Therapies for the Central Nervous System},
journal = {JAMA Neurology},
year = {2024},
volume = {81},
number = {3},
pages = {283},
doi = {10.1001/jamaneurol.2023.4983}
}
EUVIMED